Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia

Leuk Lymphoma. 1996 Aug;22(5-6):365-73. doi: 10.3109/10428199609054774.

Abstract

In this review, we summarize and update our data on the development of a multi-unit anti-BCR/ABL ribozyme. In vitro studies comparing several anti-BCR/ABL ribozymes demonstrated that a triple-unit ribozyme is the most efficient. Detailed kinetic analysis revealed this ribozyme to have a lower Kcat, most likely due to non homologous bases at restriction enzyme sites used in ribozyme construction. Delivery of this ribozyme to a BCR/ABL transformed cell line by a novel vehicle targeting the folate receptor resulted in a 3 log reduction in BCR/ABL mRNA when analyzed by RT-PCR. This delivery strategy reversed the IL-3 independence of this cell line. Retroviral vectors containing genes coding for the multi-unit ribozyme have been constructed and their use to effect BCR/ABL transformed cell biology is discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Base Sequence
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / biosynthesis
  • Fusion Proteins, bcr-abl / genetics
  • Genetic Therapy*
  • Humans
  • Kinetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Molecular Sequence Data
  • RNA, Catalytic / chemistry
  • RNA, Catalytic / metabolism
  • RNA, Catalytic / therapeutic use*
  • RNA, Messenger / metabolism
  • Substrate Specificity
  • Transfection
  • Tumor Cells, Cultured

Substances

  • RNA, Catalytic
  • RNA, Messenger
  • Fusion Proteins, bcr-abl